Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$38 Mln
Revenue (TTM)
$2 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
7.6
Industry P/E
--
EV/EBITDA
0.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-4.3
Face value
--
Shares outstanding
8,648,620
CFO
$-207.76 Mln
EBITDA
$-302.35 Mln
Net Profit
$-292.40 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lumos Pharma (LUMO)
| 36.5 | -0.5 | 16.4 | 51.7 | -17.6 | -21.4 | -35.0 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Lumos Pharma (LUMO)
| -11.9 | -47.9 | -80.6 | 56.8 | 66.4 | -81.1 | -21.1 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lumos Pharma (LUMO)
|
4.3 | 37.5 | 2.2 | -34.9 | -1,302.3 | -312.4 | -- | 7.6 |
| 60.0 | 2,342.0 | 0.0 | -76.3 | -1,093,125.0 | -25.9 | -- | 8.5 | |
| 13.3 | 21.1 | 1.4 | -16.0 | -1,156.1 | -83.5 | -- | 1.1 |
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral... growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. As of December 12, 2024, Lumos Pharma, Inc. was taken private. Read more
Founder, CEO & Chairman
Mr. Richard J. Hawkins
Founder, CEO & Chairman
Mr. Richard J. Hawkins
Headquarters
Austin, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Lumos Pharma Inc (LUMO) is $4.34 (NASDAQ) as of 13-Dec-2024 09:30 EDT. Lumos Pharma Inc (LUMO) has given a return of -17.65% in the last 3 years.
Since, TTM earnings of Lumos Pharma Inc (LUMO) is negative, P/E ratio is not available.
The P/B ratio of Lumos Pharma Inc (LUMO) is 7.64 times as on 13-Dec-2024, a 94 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.76
|
0.94
|
|
2022
|
-0.96
|
0.50
|
|
2021
|
-1.90
|
0.65
|
|
2020
|
-52.29
|
2.54
|
|
2019
|
-0.24
|
0.13
|
The 52-week high and low of Lumos Pharma Inc (LUMO) are Rs -- and Rs -- as of 03-Apr-2026.
Lumos Pharma Inc (LUMO) has a market capitalisation of $ 38 Mln as on 13-Dec-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Lumos Pharma Inc (LUMO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.